


11/04/2008

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on October 23, 2008.



Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 C.F.R. § 1.116
Examining Group 1617
Patent Application
Docket No. MET-037CXT
Serial No. 09/900,364

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Yong Soo Chong
Art Unit : 1617
Applicants : Paul D. van Poelje, Mark D. Erion, Toshihiko Fujiwara
Serial No. : 09/900,364
Filed : July 5, 2001
Conf. No. : 7049
For : Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

AMENDMENT UNDER 37 C.F.R. § 1.116

Sir:

Applicants request that the period for response be extended one month through and including October 23, 2008, the fees for which have been paid at the time this Amendment was filed.

In response to the Office Action dated June 23, 2008, please amend the above-identified patent application as follows: